Syros Pharmaceuticals stock: Next results date is October 29, 2026 for Syros Pharmaceuticals stock

Syros Pharmaceuticals stock is scheduled for its next report on October 29, 2026, while the company profile centers on a 68-person biotechnology business developing medicines that regulate gene expression. TradingView lists October 29, 2026 as the next earnings date for Syros Pharmaceuticals.

A 68-person biotechnology profile

Syros Pharmaceuticals focuses on small-molecule medicines for cancers and single-gene diseases. Its pipeline includes tamibarotene, an oral therapy being studied in genetically defined blood cancers, alongside SY-2101 and SY-5609.

The company profile identifies James E. Bradner as chief executive and places the business in the healthcare and biotechnology industries. Syros Pharmaceuticals was founded in 2011 and completed its initial public offering on June 30, 2016.

What date comes next?

The October 29, 2026 reporting date is the next scheduled company event identified by TradingView. The date gives investors a concrete point for reviewing the company's pipeline, financial position and corporate status.

Corporate status shapes the context

The company website lists a voluntary delisting from Nasdaq and SEC deregistration among its corporate updates. That status is material for interpreting the security because the business profile and the quoted-market history no longer describe a conventional actively listed biotechnology stock. Syros Pharmaceuticals presents the delisting notice alongside its gene-control research programs.

Pipeline remains the central business fact

Syros Pharmaceuticals describes gene expression as the foundation of its discovery platform. Its lead program, tamibarotene, has been studied in higher-risk myelodysplastic syndrome and acute myeloid leukemia, while the company also lists earlier-stage programs in oncology.

Market context: Market report S&P 500.

More news and analyses on Syros Pharmaceuticals stock